Pain perception is a complex experience, the initiation of which is mediated, among others, by voltage-gated sodium channels. Pathogenic variants in the sodium channel gene SCN11A encoding for NaV1.9 have been associated with various pain loss and neuropathic pain conditions. We herein describe the novel heterozygous SCN11A variant c.197A>C; p.(Tyr66Ser) that is absent in controls and cosegregates with small fiber neuropathy in a mother-and-son duo. To a variable degree, but progressively over time, both patients developed positive and negative sensory symptoms and milder autonomic signs. Upon quantitative sensory testing, we found significant thermal hypoesthesia and pinprick hyperalgesia in both individuals. Rectangle, half-sine-, and sine-wave stimulation applied to hands and feet in both individuals revealed signs of axonal on/off-like hyperexcitability, possibly due to continuous activation of CMi-fibers that are insensitive to mechanical stimulation (also known as sleeping nociceptors). Nerve conduction studies were unremarkable, whereas pain-related evoked potentials showed pathological responses in both individuals. The intraepidermal nerve fiber density was reduced at the index patient’s distal leg. Patch-clamp analyses revealed that p.(Tyr66Ser) shifted both the voltage dependence of activation and steady-state inactivation of NaV1.9 to more depolarized potentials, accompanied by accelerated deactivation and a slowdown of the channel’s inactivation kinetics. In addition, overexpression of the variant in mouse sensory neurons shortened the duration of individual action potentials and enhanced action potentials after hyperpolarization. In this translational n-of-two study, we present longitudinal data on disease progression and provide functional evidence that the SCN11A variant p.(Tyr66Ser) is a strong candidate to contribute to the patients’ phenotype.
Altered NaV1.9 channel activity in two Tyr66Ser variant carriers with small fiber dysfunction
Disclosures: A. Lampert reported personal fees from Grünenthal during the conduct of the study. R. Rolke reported personal fees from Aristo Pharma, Avextra, Cannamedical, Grünenthal, Tilray Germany, and EISAI outside the submitted work; and being cospeaker of the physicians´ section of the German Association of Palliative Medicine. M.F. Dohrn reported personal fees from AstraZeneca, Alnylam, Pfizer, and Applied Therapeutics outside the submitted work. No other disclosures were reported.
This work is part of a special issue on voltage-gated sodium (Nav) channels.
- Award Id(s): TN1-1/IA 532001,TN1-2/IA 532002,TN1-6/IA 532006,TN1-9/IA 532009
- Award Id(s): 13 GW0334B
- Award Id(s): KU 1587/6-1,KU 1587/9-1,KU 1587/10-1,KU 1587/11-1,363055819/GRK2415,368482240/GRK2416,LA 2740/6-1,LE 2338/3-2,WE 1406/17-1,NA 970 7-1
- Award Id(s): N° 825575
Noortje W.M. van den Braak, Samuel Kuehs, Greta Z. Peschke, Barbara Namer, Annette Lischka, Katja Eggermann, Christina Dumke, Vishal Sudha Bhagavath Eswaran, Stefan Nikolin, Joachim Weis, Jörg B. Schulz, Angelika Lampert, Ingo Kurth, Roman Rolke, Enrico Leipold, Maike F. Dohrn; Altered NaV1.9 channel activity in two Tyr66Ser variant carriers with small fiber dysfunction. J Gen Physiol 3 November 2025; 157 (6): e202413691. doi: https://doi.org/10.1085/jgp.202413691
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement